# Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above

> **NCT04100772** · PHASE1 · COMPLETED · sponsor: **CanSino Biologics Inc.** · enrollment: 237 (actual)

## Conditions studied

- Pneumococcal Infections
- Streptococcal Infections
- Bacterial Infections

## Interventions

- **BIOLOGICAL:** 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine（CRM197,TT）
- **BIOLOGICAL:** 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine

## Key facts

- **NCT ID:** NCT04100772
- **Lead sponsor:** CanSino Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-18
- **Primary completion:** 2021-06-23
- **Final completion:** 2022-08-23
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2022-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04100772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04100772, "Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04100772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*